Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs Twist Bioscience Corp — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $27.69, while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| KOLD | TWST | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $102.88 |
52-Week Low | $13.58 | $24.16 |
Market Cap | — | $5.45B |
Enterprise Value | — | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD, a natural gas-focused ETF, trades at $28.25, up 4.01% today with strong bullish momentum from moving averages. Technical indicators show overbought conditions with RSI readings above 70, while ADX signals strong trend direction. Recent news highlights natural gas market volatility driven by weather forecasts and storage reports, with the EIA projecting record supply and demand for 2026.
The outlook remains tactical with heightened volatility expected from weather patterns and LNG export flows. Investment opportunities exist for short-term traders using KOLD as a hedging instrument, though overbought technicals and natural gas price sensitivity pose near-term risks. The ETF's performance is directly tied to natural gas futures price movements and market sentiment.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
